2篇
您的检索式：作者名="Emanuela Ferraro"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Opportunities and challenges of implementing Pharmacogenomics in cancer drug development显示文摘Cancer drug development is a time and resources consuming process.Around 90%of drugs entering clinical trials fail due to lack of efficacy and/or safety issues,more often after conspicuous research and economic efforts.Part of the discarded drugs might be beneficial only in a subgroup of the study patients,and some adverse events might be prevented by identifying those patients more vulnerable to toxicities.The implementation of pharmacogenomic biomarkers allows the categorization of patients,to predict efficacy and toxicity and to optimize the drug development process.Around seventy FDA approved drugs currently present one or more genetic biomarker to keep in consideration,and with the progress of Precision Medicine tailoring therapies on individuals’genomic landscape promises to become a new standard of cancer care.In the current article we review the role of pharmacogenomics in cancer drug development,underlying the advantages and challenges of their implementation. | Paolo Tarantino Dario Trapani Stefania Morganti Emanuela Ferraro Giulia Viale Paolo D’Amico Bruno Achutti Duso Giuseppe Curigliano | 2019 | Cancer Drug Resistance2019，2，1： | 1 |
| 2 | Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls显示文摘Loss of HER2 in previously HER2-positive breast tumors is not rare, occurring in up to 50% of breast cancers;however, clinical research and practice underestimate this issue. Many studies have reported the loss of HER2 afterneoadjuvant therapy and at metastatic relapse and identified clinicopathological variables more frequentlyassociated with this event. Nevertheless, the biological mechanisms underlying HER2 loss are still poorlyunderstood. HER2 downregulation, intratumoral heterogeneity, clonal selection, and true subtype switch have beensuggested as potential causes of HER2 loss, but translational studies specifically investigating the biology behindHER2 loss are virtually absent. On the other side, technical pitfalls may justify HER2 loss in some of these samples.The best treatment strategy for patients with HER2 loss is currently unknown. Considering the prevalence of thisphenomenon and its apparent correlation with worse outcomes, we believe that correlative studies specificallyaddressing HER2 loss are warranted. | Stefania Morganti Mariia Ivanova Emanuela Ferraro Liliana Ascione Grazia Vivanet Giuseppina Bonizzi Giuseppe Curigliano Nicola Fusco Carmen Criscitiello | 2022 | Cancer Drug Resistance2022，5，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员